Clinical Trial Update: MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D) [Phase 2]

View source ↗

Summary

This update notes the completion of a Phase 2, dose-ranging study evaluating anti-thymocyte globulin (ATG) within six weeks of Type 1 diabetes onset.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Universitaire Ziekenhuizen KU Leuven | Conditions: Diabetes Mellitus, Type 1 | Phase 2 | Status: COMPLETED